Should Mylan be able to charge whatever it wants for the EpiPen? | The Tylt

FINAL RESULTS
Politics
Should Mylan be able to charge whatever it wants for the EpiPen?
#LetBizDecide
A festive crown for the winner
#HealthOverProfits

Pharmaceutical company Mylan is facing intense public scrutiny over the pricing of its EpiPens, a life-saving prescription medication for those suffering from severe allergic reactions. Experts say the EpiPen costs just a few dollars to make, while Mylan charges over $600 for a pack of two. When Mylan purchased the EpiPen from Merck in 2007, each pen cost $57 each. Many health care advocates are accusing Mylan of price-gouging, but CEO Heather Bresch denies the charge—and is offering some customers steep discounts on EpiPens.

Tell us what you think: Should we #LetBizDecide prescription prices or do you believe in #HeathOverProfits? Vote below!

Dataviz
Real-time Voting
Should Mylan be able to charge whatever it wants for the EpiPen?
#LetBizDecide
#HealthOverProfits
#LetBizDecide
Mylan CEO Heather Bresch said the complex supply chain in healthcare is to blame for the price increase: "This system needs to be fixed. No one knows what anything costs."
#LetBizDecide
Mylan doesn't even get most of the money from the EpiPen price hike! CEO Heather Bresch said the price is the result of a system where "four or five hands that the product touches and companies that it goes through before it ever gets to that patient at the counter. That $608 is a list price. What Mylan takes from that, our net sales is $274, so $137 per pen."
#LetBizDecide
Plus, Mylan already offers steep discounts on its EpiPen to some patients.
#LetBizDecide
And the argument that you can't get an alternative is not entirely true. You can ask your doctor for a generic.
#HealthOverProfits
But critics argue there's no denying Heather Bresch has gotten rich by jacking the price on patients with life-threatening allergies.
#HealthOverProfits
Mylan CEO Heather Bresch is also the daughter of a U.S. Senator, and has a history of questionable business practices.
#HealthOverProfits
Democratic presidential nominee Hillary Clinton has also come out against Mylan's price hike.
#HealthOverProfits
And Mylan has a near-monopoly in the market, thanks to the lack of FDA regulations—putting the cost of the EpiPen out of reach for many working class families.
#HealthOverProfits
#HealthOverProfits
#HealthOverProfits
FINAL RESULTS
Politics
Should Mylan be able to charge whatever it wants for the EpiPen?
#LetBizDecide
A festive crown for the winner
#HealthOverProfits